InnoCare Pharma (FRA:33C) COGS-to-Revenue : 0.14 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma COGS-to-Revenue?

InnoCare Pharma's Cost of Goods Sold for the three months ended in Dec. 2023 was €3.54 Mil. Its Revenue for the three months ended in Dec. 2023 was €25.84 Mil.

InnoCare Pharma's COGS to Revenue for the three months ended in Dec. 2023 was 0.14.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. InnoCare Pharma's Gross Margin % for the three months ended in Dec. 2023 was 86.31%.

InnoCare Pharma COGS-to-Revenue Historical Data

The historical data trend for InnoCare Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma COGS-to-Revenue Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.06

0.23

0.17

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial												0.24	-	0.16	0.14	0.15

InnoCare Pharma COGS-to-Revenue Calculation

InnoCare Pharma's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	16.495	/	94.849
	=	0.17

InnoCare Pharma's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3.538	/	25.836
	=	0.14

InnoCare Pharma (FRA:33C) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

InnoCare Pharma's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	3.538 / 25.836
	=	86.31 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

InnoCare Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (FRA:33C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

09969:Hong Kong 33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines